- Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889S Eralp Bellibas
Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, New Jersey, USA
Clin Cancer Res 10:2327-35. 2004..This study assessed the tolerance to Ro 09-4889 treatment, and related pharmacokinetic and pharmacodynamic data such as inhibition of DPD activity in peripheral blood mononuclear cells (PBMCs) and plasma uracil levels...
- Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapyS Eralp Bellibas
Roche, Nutley, NJ 07110, USA
Pediatr Infect Dis J 23:1137-41. 2004..Enfuvirtide is the first of a new class of antiretroviral agents, the fusion inhibitors...
- Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patientsKiat Ruxrungtham
Thai Red Cross AIDS Research Centre, Rama 4 Road, Bangkok 10330, Thailand
J Clin Pharmacol 44:793-803. 2004..Thus, no dosage adjustments are warranted when enfuvirtide is coadministered with low-dose ritonavir or saquinavir boosted with a low dose of ritonavir...